C9orf93 Inhibitors
C9orf93 inhibitors encompass a range of compounds that influence cellular signaling pathways and biological processes in a way that leads to the functional inhibition of C9orf93. These chemical inhibitors act indirectly by modulating the cellular environment or directly interfering with molecular mechanisms that are crucial for the proper functioning of C9orf93. For instance, inhibitors that target epigenetic regulators may alter gene expression patterns, potentially suppressing the expression of C9orf93 if its regulation is dependent on such processes. Similarly, compounds that inhibit key signaling molecules, such as mTOR, can disrupt pathways required for C9orf93 expression or activation, thereby diminishing its activity. In addition, broad-spectrum kinase inhibitors may block essential phosphorylation events needed for C9orf93 function, rendering the protein inactive.
Moreover, inhibitors that interfere with cellular metabolism, protein synthesis, and trafficking can indirectly reduce the functional activity of C9orf93. For example, by inhibiting glycolysis, a compound can create an energy deficit that could impair the energy-dependent functions of C9orf93. Agents that halt protein synthesis or transport would prevent the production or correct localization of C9orf93, leading to its functional inhibition. Proteasome inhibitors may also induce cellular stress and disrupt proteostasis, potentially affecting C9orf93 stability or interaction with other proteins. Additionally, chemicals affecting calcium signaling or specific kinase pathways can lead to a reduction in C9orf93 activity if it is regulated by or associated with these pathways.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
This histone deacetylase inhibitor leads to hyperacetylation of histones, affecting the chromatin structure and potentially altering the expression of various genes. If C9orf93 is regulated by chromatin remodeling, such hyperacetylation might suppress its expression or affect its function by altering the interaction of chromatin with coiled-coil domain-containing proteins. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
As an mTOR inhibitor, rapamycin disrupts the mTOR signaling pathway, which is involved in protein synthesis and cell growth. If C9orf93 is a protein that requires mTOR pathway activation for its expression or function, inhibition by rapamycin would decrease C9orf93 activity. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
This potent kinase inhibitor has a broad range of targets and could disrupt multiple phosphorylation events within cells. If C9orf93 function is dependent on phosphorylation by specific kinases, staurosporine might indirectly inhibit C9orf93 by preventing its necessary phosphorylation. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $65.00 $210.00 | 26 | |
This glucose analog inhibits glycolysis by interfering with glucose metabolism. If C9orf93 is involved in cellular processes that require energy from glycolysis, its function could be indirectly inhibited due to an energy deficit caused by 2-deoxy-D-glucose. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $40.00 $82.00 $256.00 | 127 | |
This chemical inhibits eukaryotic protein synthesis by interfering with the translocation step in protein elongation. If C9orf93 protein synthesis is actively occurring, cycloheximide would inhibit its production, thereby decreasing its functional activity. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
An inhibitor of protein transport from the endoplasmic reticulum to the Golgi apparatus, brefeldin A could disrupt the proper localization and functioning of C9orf93 if it is a protein that undergoes this transport process. | ||||||
Dimethyl Sulfoxide (DMSO) | 67-68-5 | sc-202581 sc-202581A sc-202581B | 100 ml 500 ml 4 L | $30.00 $115.00 $900.00 | 136 | |
This solvent can disrupt membrane structure and protein-protein interactions. If C9orf93 relies on specific protein-protein interactions for its function, DMSO might inhibit these interactions and thus the function of C9orf93. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
This proteasome inhibitor can prevent the degradation of proteins, leading to an accumulation of misfolded or damaged proteins. If C9orf93 is involved in proteostasis, its function might be inhibited by the stress and imbalances caused by proteasome inhibition. | ||||||
W-7 | 61714-27-0 | sc-201501 sc-201501A sc-201501B | 50 mg 100 mg 1 g | $163.00 $300.00 $1642.00 | 18 | |
As a calmodulin antagonist, W-7 interferes with calcium signaling by inhibiting calmodulin-dependent processes. If C9orf93 function is calcium-dependent or interacts with calmodulin-regulated pathways, this inhibitor could indirectly diminish the protein's activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
This compound specifically inhibits MEK, which is part of the MAPK/ERK pathway. If C9orf93's activity or stability is regulated by this signaling pathway, inhibition of MEK could lead to a decrease in C9orf93 functional activity. | ||||||